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ABSTRACT 
 
Background 
We identified a new and a recurrent POLD1 mutation associated with predisposition 
to colorectal cancer (CRC). We characterized the molecular and clinical nature of the 
potential POLD1 founder mutation in families from Valencia (Spain). 
Methods 
Clinical and molecular data were collected from 4 independent families known to 
have a POLD1 Leu474Pro mutation. To establish its founder effect, haplotype 
construction was performed using 14 flanking POLD1 polymorphic markers. We 
calculated penetrance estimates and clinical expressivity, globally and stratified by 
age and sex. 
Results 
We included 32 individuals from the 4 families: 20 carriers and 12 noncarriers. A 
common haplotype was identified in these families in a region comprising 2.995 Mb, 
confirming L474P as the first founder POLD1 mutation identified. Thirteen tumors 
diagnosed in 10 POLD1 carriers: 8 CRC, 3 endometrial, and two other tumors were 
considered. The median age of cancer onset for POLD1 mutation carriers was 48 
years. The observed penetrance was 50% and the cumulative risk at age of 50 was 
30%. 
Conclusions 
Our findings contribute to a better understanding of CRC genetics in the Spanish 
population. The clinical phenotype for this mutation is similar to that in Lynch 
syndrome. Future studies using NGS with large gene panels for any hereditary 
cancer condition will offer the possibility to detect POLE/POLD1 mutations in 
unsuspected clinical situations showing a more real and unbiased picture of 
the associated phenotype. 
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INTRODUCTION 
 
Polymerase proofreading-associated polyposis (PPAP) has been proposed as a new 
hereditary cancer condition with high-penetrance, dominant inheritance, 
characterized by multiple colorectal adenomas and carcinomas and caused by 
germline mutations in the genes encoding the catalytic subunits of the DNA 
polymerases Pol  and Pol  (POLD1 and POLE, respectively)1. A major role of Pol  
in both the leading and lagging DNA strands has been described.2 
This new entity emerged from the findings of The Cancer Genome Atlas project on 
colorectal cancer (CRC), in which a subset of ultramutated tumors with absence of 
microsatellite instability (MSI) and recurrent somatic mutations in POLE exonuclease 
domain was identified.3 The number of germline POLD1/POLE proofreading domain 
mutations analyzed to date is relatively modest, and the majority of cases have been 
found to have microsatellite stable tumors,1,4 even though MSI has been noted in 
some cases.5 The most common germline mutations found to date are POLE L424V 
and POLD1 S478N, although an increasing number of other different pathogenic 
variants are being identified.1 The PPAP phenotype overlaps that of Lynch syndrome 
(LS) and MUTYH-associated polyposis (MAP), and the proposed screening and 
management algorithms are broadly similar. The analysis of POLE and POLD1 is 
included in the diagnostic algorithm for these 2 cancer syndromes.6 
We previously reported a new pathogenic POLD1 variant (L474P) in 2 independent 
families classified as having familial CRC type X.6,7 The finding of 2 other, apparently 
unrelated families from the same population drove us to establish its founder effect 
and its phenotype description. 
 
MATERIALS AND METHODS 
 
Patients, DNA, tissue samples, and clinicopathological information 
Members from 4 nonpolyposis hereditary CRC families known to carry the POLD1-
Leu474Pro mutation were recruited through the Hereditary Cancer Program of the 
Valencian region between 2005 and 2016. In addition, blood DNA from 30 healthy 
individuals was used to analyze the haplotype frequency in controls. Biological 
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samples and clinicopathological information were obtained from the Valencian 
Biobank Network and from the Hereditary Cancer Program of the Valencian region, 
both in Spain. The study was approved by the Ethics Committee of the Department 
of Public Health of the Valencian region. 
Diagnostic algorithm of the nonpolyposis hereditary CRC 
Clinical and pathological criteria (Amsterdam and Bethesda criteria) were used as 
the first tier for hereditary CRC suspicion. Alternatively, universal screening of CRC 
and endometrial cancer, diagnosed below the age of 71 years by 
immunohistochemistry (IHC) of the mismatch repair (MMR) proteins, is also 
considered. MMR status in tumor tissue was assessed either by IHC of the MMR 
proteins or by PCR-based MSI analysis, or both. MLH1 promoter methylation and 
BRAF_V600E mutation in tumor tissues was analyzed when MLH1 loss of 
expression was detected. Families fulfilling Amsterdam II criteria with normal 
expression of MMR proteins or microsatellite stable tumors were considered as 
familial CRC type X, and genetic analysis of POLE and POLD1 was performed. 
When loss of MMR protein expression in tumors was found, the germline analysis of 
the involved gene was assessed. 
Germline mutation analysis 
Germline mutation studies were performed on DNA isolated from peripheral blood 
leucocytes. Sanger sequencing was used to screen for mutations in exons where the 
most frequent mutations are located (exon 13 of POLE, and exon 11 of POLD1). 
Primers and PCR conditions are published elsewere.7 Detection of point mutations in 
MLH1 was conducted using PCR and direct sequencing of the whole coding 
sequence and intron–exon boundaries for each gene and large rearrangements 
analysis by MLPA.8 Sequencing was performed using a 3130 Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA), and data were analyzed using 
Sequencing Analysis, version 5.1, and Variant Reporter, version 1.1, software 
(Applied Biosystems). 
Microsatellite genotyping and haplotype analysis 
Haplotypes were constructed manually from 3 SNPs (rs7246646, rs1363756, and 
rs12975011) and 11 POLD1 flanking microsatellite markers (D19S420, D19S902, 
D19S879, D19S867, D19S904, D19S907, D19S206, D19S921, D19S927, D19S891, 
D19S887) expanding 13.818 Mb and assuming the lowest number of 
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recombinations. References, primer sequences, and PCR conditions are described 
in Table S1. SNP analysis was performed by allelic discrimination using real-time 
PCR with TaqMan probes (Applied Biosystems). Microsatellite marker analysis was 
performed with one fluorescently labeled primer per set according to standard 
procedures. Fragment analysis was performed using an ABI3130 analyzer with 
GeneMapper software (Applied Biosystems). Mutation age was estimated with the 
single marker method,9 using affected and nonaffected chromosomes from the 
available members of the studied families. 
 
 
RESULTS 
 
We included 32 individuals from the 4 known families with the POLD1-Leu474Pro 
mutation: 28 were genetically tested individuals: 16 carriers and 12 noncarriers. In 
addition, 3 affected and obligated carriers were also considered. We exhausted the 
DNA from one mutated case that was excluded from the haplotype analysis. 
Haplotype analysis and estimation of mutation age 
We found a minimum common haplotype for all 16 mutation carrier individuals 
analyzed from the 4 families. The common haplotype extended from D19S904 to 
D19S921 markers and represented a size of 2.995 Mb (Table 1, Table S2).  
Thirty control individuals were genotyped for the microsatellite markers that define 
the common haplotype. We calculated the allelic frequency for each allele 
composing the minimum common haplotype. The estimated frequency of the 
common haplotype in controls was 1.25· 10–6 (Table S3). The resulting ages are 4 
and 28 generations (100 to 700 years) for recombinant markers D19S867 and 
D19S927, respectively. 
Characterization of the clinical phenotype associated 
The first family we found with this new mutation in POLD1 was published by Valle et 
al.7 This family meets Amsterdam II criteria, without alteration of the MMR system, 
being considered as having familial CRC type X. The mutation in this family was 
identified in 2 women affected by multiple tumors and in a healthy woman (Figure 
S1). The pathogenicity assessment of this mutation was established based on 
various lines of evidence. The Leu474 of POLD1 is the paralog residue to the 
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Leu424 in POLE, which is clearly pathogenic. Moreover, it is highly evolutionally 
conserved, various in silico prediction programs suggest its pathogenicity, and 
functional in vitro studies (in yeast) show a loss of polymerase functionality, 
producing a mutator phenotype. The mutation cosegregated with the disease in the 
family.7 
The second family found with this mutation was described by Bellido et al.6 This 
family, apparently unrelated to the previous family, met Amsterdam I criteria, with 
both microsatellite stable (MSS) and MSI cases (loss of MSH6), in which the 
mutation has been identified in 7 individuals: 2 healthy and 5 diagnosed with CRC, 
and colonic and gastric polyps (Figure S2). 
More recently, we have identified this mutation in a third independent family. This 
family consists of a woman who developed CRC at age 51 years with no family 
history of cancer who was identified by the universal screening of MMR proteins. 
Tumor tissue analysis showed loss of expression of MLH1 and PMS2, MSI, with 
absence of MLH1 methylation and BRAF mutation. No germline mutation in MLH1 
was detected (Figure S3). Furthermore, analysis of somatic MLH1 mutation in her 
tumor showed a homozygous/hemizygous nonsense pathogenic variant [c.1279C>T; 
p.(Glu427*)]. 
The fourth independent family with the same germline mutation in POLD1 fulfilled 
Bethesda criteria. The proband was diagnosed with a CRC and a breast cancer at 
ages 45 and 52, respectively. Her father was found to have a CRC at age 83. Tumor 
analysis of the proband showed a normal expression of the MMR proteins and MSS 
(Figure S4). 
In summary, 13 tumors diagnosed in 10 carrier patients (8 CRC, 3 endometrial 
cancers, a GIST and a breast cancer), an esophageal benign tumor and colorectal 
oligopolyposis (3 adenomas) in another 3 patients were considered. The median 
age of cancer onset for all POLD1 mutation carriers was 48 years (range 23–80 
years). The observed penetrance was 50% (40% in males and 53% in females). The 
cumulative risk at age 50 was 30% (40% in males and 27% in females) (Table 2). 
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DISCUSSION 
 
To our knowledge, the 4 Valencian families included in this study are the only 
families where the POLD1 Leu474Pro mutation has been found. The Valencian 
Community is located on the south-east Mediterranean coast of Spain, with a 
population of about 5 million people. The limited geographical dispersion of the 4 
families, an area with an expanse of about 350 km, and the existence of a clear 
shared haplotype in carrier individuals, strongly suggests a common ancestor for 
these families. This mutation is unambiguously responsible for the high risk of cancer 
seen in these families. When we estimated the mutation age we obtained a wide 
range in the number of generations. This is because of the methodological limitation 
of the single marker method, especially when the distances of the first recombinant 
marker from both sides of the mutation are asymmetric. Therefore, these results 
must be viewed with caution. The POLD1 Leu474Pro is the first founder mutation 
described in this gene to date. Likely, a broad incorporation of POLE/POLD1 testing 
in the hereditary cancer diagnosis could unveil new founder mutations in these 
genes. 
Founder mutations have been proven to impact upon molecular diagnosis strategies 
in specific populations; where they can be assessed as the first screening step, and 
if positive, avoid the expense of further gene scanning. This is valid even at a time 
when next generation sequencing (NGS) is been introduced in the molecular 
diagnosis of hereditary cancer syndromes. The inclusion of new genes or amplicons 
containing the founder mutations in the NGS gene panels makes possible a most 
effective and efficient identification of pathogenic mutations.10 
Families 1 and 2 were classified as familial CRC type X and family 4 fulfilled 
Bethesda criteria with a MMR proficient tumor. Consequently, no further genetic 
studies could be offered for these 3 families according to the classical diagnostic 
algorithm for LS. Family 3 does not fulfil the Bethesda criteria and was referred to the 
Genetic Counseling in Cancer Unit for prospective universal screening of all CRC by 
IHC of MMR proteins. This case was classified as “Lynch-like syndrome” until further 
evidence could determine the somatic or hereditary origin of this tumor. The finding 
of the germline POLD1 mutation made us wonder whether the loss of MLH1 
expression could be the result of MLH1 somatic mutations as a consequence of the 
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POLD1 inactivation. Effectively, we found a MLH1 somatic homozygous/hemizygous 
nonsense mutation that could explain the loss of expression. Recently, Jansen et al., 
have published similar findings in another case and suggest that faulty proofreading 
may result in loss of MMR and thereby in MSI.5 These investigators also emphasize 
the importance of POLE/POLD1 germline and somatic screening in unexplained 
MMR-deficient tumors. The fact that germline mutations in non-MMR genes can 
mimic LS has been previously reported in MUTYH. Biallelic mutation in this gene is 
able to produce somatic mutations in MMR genes imitating the molecular and 
pathological phenotype of Lynch tumors.11-12 
We acknowledge a limitation regarding to the clinical phenotype associated with this 
founder mutation. There is a bias in the POLD1 studied population, because only 
unexplained cases of LS have been tested in our region. It is possible that some 
patients from the Valencian region with unexplained cases of MAP syndrome could 
also carry this founder mutation. The phenotype overlapping PPAP with LS and MAP 
syndromes, sustains broadly similar screening recommendations and management 
algorithms,1,6 which are also suitable for this founder mutation. 
New high-throughput technology is unveiling an increasing complexity of the 
underlying genetic background responsible for familial cancer syndromes. The 
discovery of a high level of genetic heterogeneity and variable expressivity, with a 
substantial phenotypic overlap among the defined syndromes, makes necessary a 
constant re-evaluation of the diagnostic approaches and algorithms, as well as the 
definition of new hereditary scenarios for cancer susceptibility. The PPAP syndrome 
is a good example of this, although in many cases polyposis is not the relevant 
phenotype of the syndrome.1 
Leu474Pro is the first founder mutation in POLD1 described to date. Future studies 
using NGS with large gene panels for any hereditary cancer condition will offer the 
possibility of detecting POLE/POLD1 mutations in unsuspected clinical situations 
showing a more real and unbiased picture of the associated phenotype. 
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Table 1. Minimum common haplotype. 
The common haplotype is depicted, showing the minimal common region among the 4 families. All analyzed carriers of the 
c.1421T>C variant shared a common haplotype comprising the region between D19S904 and D19S921. Minimum common 
haplotype: 2,995 Mb. Estimated frequency of the common haplotype in controls: 1 in 1.2 million. 
 
 
Marker D19S420 D19S902 D19S879 rs7246646 D19S867 D19S904 
POLD1 
c.1421T>C 
D19S907 rs1363756 rs12975011 D19S206 D19S921 D19S927 D19S891 D19S887 
                
Position (Mb) 43.305 47.829 49.013 49.140 50.035 50.273 50.406 50.558 50.632 51.348 52.048 53.268 53.795 55.522 57.122 
Family 1 263 199 240 G 98 207 Yes 216 G G 138 233 138 170 253/249 
Family 2 263 213 244 G 104 207 Yes 216 G G 138 233 138 184 255 
Family 3 271 209 240 G 104 207 Yes 216 G G 138 233 128 170 247 
Family 4 271/257 209 240 G 104 207 Yes 216 G G 138 233 128 170 249/255 
                                                                                                                                                                                             2.995 Mb 
                                                                                                                                                                                             3.233 Mb 
 
 
    
D19S867 D19S904 
POLD1 
c.1421T>C 
D19S907 rs1363756 rs12975011 D19S206 D19S921 D19S927 
Shared alleles    104 207 Yes 216 G G 138 233 138 
Control 
frequencies 
(%) 
   21.6 25 0 1.7 47 47 3.3 11.7 34.5 
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Table 2. Clinical and histopathological information of POLD1: c.1421T>C carriers and obligated carriers.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               ND, 
not determined. 
 IDENTIFICATION SEX AGE DIAGNOSIS TUMOR TYPE AND POLYPS LOCALIZATION STAGE 
 F1-II-2 F 52 Adenocarcinoma Endometrium ND 
 F1-II-6 F 39 Adenocarcinoma Colon IIA 
FAMILY 1 56 Adenocarcinoma Endometrium II 
 F1-III-1 F 35 Adenocarcinoma Sigmoid Colon I 
  35 GIST Small Intestine IA 
 F2-II-1 M 42 Adenocarcinoma Colon IV 
 F2-III-2 F 48 Polyp (n=1) Colon - 
 58 Adenocarcinoma Endometrium IB 
 F2-III-4 M 50 Adenocarcinoma Rectum I 
 F2-III-6 M 45 Polyp (n=1) Colon - 
FAMILY 2 47 Polyps (n=2) Colon - 
 F2-IV-1 F 23 Adenocarcinoma Left  colon I 
 31 Benign tumor Oesophagus - 
 31 Polyps (multiple) Stomach - 
 F2-IV-2 F 25 Polyp (n=1) Colon - 
 27 Polyp (n=1) Colon - 
FAMILY 3 
F3-II-6 F 80 Adenocarcinoma Colon IV 
F3-III-2 F 51 Adenocarcinoma Cecum IVB 
FAMILY 4 F4-II-2 F 
45 Adenocarcinoma Rectum III 
52 Adenocarcinoma Breast IIIA 
